AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
EMPACT-MI Results: Empagliflozin After Acute Myocardial Infarction
Apr 9, 2024
Cardiologists Javed Butler and Sun Moon Kim discuss EMPACT-MI trial results on heart failure risk post-myocardial infarction. They explore misconceptions on EF percentages, diuretics, and benefits of SGLT2 inhibitors. Real-world evidence shapes future treatment strategies.
11:27
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- EMPACT-MI trial showed 23% reduction in heart failure hospitalizations.
- Consider early SGLT2 inhibitor initiation in post-MI patients for heart failure risk reduction.
Deep dives
Impact Trial Rationale
The rationale behind the Impact trial design centered on addressing the persistent high risk of heart failure in patients post acute myocardial infarction (MI). The trial aimed to test the impact of M-Buckla Flowsen in reducing the risk of heart failure in these patients by drawing on previous positive results in high-risk populations like those with diabetes, chronic kidney disease, and known heart failure.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode